Is Johnson & Johnson's (NYSE:JNJ) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Johnson & Johnson's (NYSE:JNJ) stock increased significantly by 11% over ...
Final Trade: TEVA, JNJ, TJX, BABA
The final trades of the day with the Fast Money traders.
JNJ met main goal in late-stage trial for ulcerative colitis treatment
Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...
Johnson & Johnson (NYSE:JNJ) Goes to Court for Third Time over $10B Talc Bankruptcy Plan
Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...
Why Johnson & Johnson (JNJ) Is One of the Best Drug Stocks to Buy Now
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
Johnson & Johnson: Rich History Of Excellence Poised To Endure
Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...
Johnson & Johnson Sees Unusually High Options Volume (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ – Get Free Report) was the target of some unusual options trading on Thursday. Stock traders purchased 58,414 call options on the stock. This is an increase of ...
Johnson & Johnson (JNJ) Receives a Buy from RBC Capital
In a report released yesterday, Shagun Singh Chadha from RBC Capital initiated coverage with a Buy rating on Johnson & Johnson (JNJ – ...
Johnson & Johnson (NYSE:JNJ) Shares Sold by Sanctuary Advisors LLC
Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...
J&J begins crucial battle over $10 billion baby powder settlement
Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby ...
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...